Advanced Lung Cancer Clinical Trial
Official title:
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant Advanced Non-small Cell Lung Cancer Patients: a Multi-center, Open-label, Phase 1/2 Study
Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. KRAS-mutant NSCLC had been considered undruggable in past decades. This research sought to address a significant challenge in treating NSCLC with KRAS mutations, which are notoriously difficult to target effectively. Here, we proposal that the combined use of anlotinib and trametinib combined with tislelizumab may form an effective strategy for the treatment of KRAS-mutant NSCLC patients.
This is a phase 1/2, open-label, multi-center study aimed at exploring the potential therapeutic efficacy of tislelizumab (intravenous), trametinib (oral) and anlotinib (oral) in KRAS-mutant advanced non-small cell lung cancer patients. The primary objectives were safety, recommended phase 2 dose (RP2D) in Phase I and PFS in Phase II. The secondary aim of the study is to evaluate the progression-free survival (PFS), overall survival (OS), adverse events (AEs), and duration of response (DOR) of the combined strategy in these patients. If the RP2D is reached in Phase I, Phase II will be started; if RP2D is not reached in Phase I, Phase II will not be started. The number of subjects is determined according to the actual situation of dose climbing. All patients will be of histo- and/or cytopathology confirmed. Determination of the KRAS mutation type will be performed in the pathological department of Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine. Both ARMS method or targeted sequencing are acceptable. It is not acceptable for subjects with the presence of other driver gene mutation. All eligible subjects must have adequate renal, hepatic, and hematologic function, as defined in "inclusion criteria". ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04575831 -
Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)
|
N/A | |
Completed |
NCT04069494 -
Descriptors and Predictors of Burden and Information Needs
|
||
Terminated |
NCT03330834 -
CAR-T Cell Immunotherapy for Advanced Lung Cancer
|
Phase 1 | |
Withdrawn |
NCT03004105 -
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Withdrawn |
NCT03501056 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05279521 -
The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.
|
N/A | |
Terminated |
NCT02768337 -
Cambridge Brain Mets Trial 1
|
Phase 1/Phase 2 | |
Completed |
NCT04672369 -
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
|
Phase 1 | |
Recruiting |
NCT03751592 -
Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05431569 -
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
|
Phase 2 | |
Recruiting |
NCT06228209 -
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
|
N/A | |
Completed |
NCT04672356 -
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Not yet recruiting |
NCT06107894 -
TIL Therapy for Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06183762 -
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
|
||
Recruiting |
NCT05664971 -
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05815862 -
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
Recruiting |
NCT06106152 -
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
|
Early Phase 1 | |
Recruiting |
NCT05000684 -
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
|
Phase 1/Phase 2 |